Triple-S Management Corporation
Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $281.06 | +0.89% | 255B | 11.76 | $23.90 | +3.02% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +2.30% |
| CI | $296.37 | +0.83% | 79.2B | 16.54 | $17.93 | +1.96% |
| CVS | $60.70 | +3.32% | 76.8B | 14.49 | $4.19 | +4.39% |
| ELV | $289.10 | +3.09% | 65.1B | 12.27 | $23.56 | +2.30% |
| HUM | $237.98 | +3.83% | 28.7B | 16.80 | $14.17 | +1.49% |
| CNC | $28.39 | +6.09% | 14.1B | 4.19 | $6.78 | N/A |
| MOH | $165.02 | +4.30% | 8.9B | 8.14 | $20.28 | N/A |
| OSCR | $14.45 | +1.76% | 3.7B | 36.11 | $0.40 | N/A |
Stock Comparison
GTS vs UNH Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 255B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $281.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 11.76. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.24%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs ANTM Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs CI Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 79.2B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $296.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 16.54. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs CVS Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 76.8B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $60.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 14.49. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.07%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs ELV Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 65.1B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $289.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 12.27. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs HUM Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 28.7B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $237.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 16.80. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.10%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 14.1B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is 4.19. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 8.9B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $165.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 8.14. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.25%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs OSCR Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 3.7B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is 36.11. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs ALHC Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 2.3B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is -25.02. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs CLOV Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 1.5B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -75.87. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.47%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs BMGL Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 42.1M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is 224.00. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here
GTS vs MRAI Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 19.5M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.45. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, GTS is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here
GTS vs NIVF Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, NIVF has a market cap of 2.2M. Regarding current trading prices, GTS is priced at $35.99, while NIVF trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas NIVF's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, GTS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check NIVF's competition here
GTS vs IVF Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, IVF has a market cap of 2.1M. Regarding current trading prices, GTS is priced at $35.99, while IVF trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas IVF's P/E ratio is -0.02. In terms of profitability, GTS's ROE is +0.07%, compared to IVF's ROE of -5.72%. Regarding short-term risk, GTS is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check IVF's competition here
GTS vs MGLN Comparison July 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here